-
Je něco špatně v tomto záznamu ?
Drugs related to monoamine oxidase activity
Z. Fišar,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NV15-28967A
MZ0
CEP - Centrální evidence projektů
- MeSH
- duševní poruchy farmakoterapie enzymologie MeSH
- inhibitory MAO chemická syntéza farmakologie terapeutické užití MeSH
- lidé MeSH
- monoaminoxidasa metabolismus MeSH
- nervový přenos účinky léků fyziologie MeSH
- neurodegenerativní nemoci farmakoterapie enzymologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Progress in understanding the role of monoamine neurotransmission in pathophysiology of neuropsychiatric disorders was made after the discovery of the mechanisms of action of psychoactive drugs, including monoamine oxidase (MAO) inhibitors. The increase in monoamine neurotransmitter availability, decrease in hydrogen peroxide production, and neuroprotective effects evoked by MAO inhibitors represent an important approach in the development of new drugs for the treatment of mental disorders and neurodegenerative diseases. New drugs are synthesized by acting as multitarget-directed ligands, with MAO, acetylcholinesterase, and iron chelation as targets. Basic information is summarized in this paper about the drug-induced regulation of monoaminergic systems in the brain, with a focus on MAO inhibition. Desirable effects of MAO inhibition include increased availability of monoamine neurotransmitters, decreased oxidative stress, decreased formation of neurotoxins, induction of pro-survival genes and antiapoptotic factors, and improved mitochondrial functions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024138
- 003
- CZ-PrNML
- 005
- 20201029153853.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pnpbp.2016.02.012 $2 doi
- 035 __
- $a (PubMed)26944656
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Fišar, Zdeněk $u Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic. Electronic address: zfisar@lf1.cuni.cz.
- 245 10
- $a Drugs related to monoamine oxidase activity / $c Z. Fišar,
- 520 9_
- $a Progress in understanding the role of monoamine neurotransmission in pathophysiology of neuropsychiatric disorders was made after the discovery of the mechanisms of action of psychoactive drugs, including monoamine oxidase (MAO) inhibitors. The increase in monoamine neurotransmitter availability, decrease in hydrogen peroxide production, and neuroprotective effects evoked by MAO inhibitors represent an important approach in the development of new drugs for the treatment of mental disorders and neurodegenerative diseases. New drugs are synthesized by acting as multitarget-directed ligands, with MAO, acetylcholinesterase, and iron chelation as targets. Basic information is summarized in this paper about the drug-induced regulation of monoaminergic systems in the brain, with a focus on MAO inhibition. Desirable effects of MAO inhibition include increased availability of monoamine neurotransmitters, decreased oxidative stress, decreased formation of neurotoxins, induction of pro-survival genes and antiapoptotic factors, and improved mitochondrial functions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a duševní poruchy $x farmakoterapie $x enzymologie $7 D001523
- 650 _2
- $a monoaminoxidasa $x metabolismus $7 D008995
- 650 _2
- $a inhibitory MAO $x chemická syntéza $x farmakologie $x terapeutické užití $7 D008996
- 650 _2
- $a neurodegenerativní nemoci $x farmakoterapie $x enzymologie $7 D019636
- 650 _2
- $a nervový přenos $x účinky léků $x fyziologie $7 D009435
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 69, č. - (2016), s. 112-24
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26944656 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20201029153851 $b ABA008
- 999 __
- $a ok $b bmc $g 1239819 $s 985051
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 69 $c - $d 112-24 $e 20160302 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
- GRA __
- $a NV15-28967A $p MZ0
- LZP __
- $a Pubmed-20170720